Skip to main content
Top
Published in: Breast Cancer Research 2/2000

01-10-2000 | Meeting abstract

The Swedish Two-County Trial 20-years on: updated mortality results and new insights from long-term follow-up

Authors: L Tabár, SW Duffy, B Viták, H-H Chen, UB Krusemo

Published in: Breast Cancer Research | Special Issue 2/2000

Login to get access

Excerpt

The Swedish Two-County Trial is a randomized controlled study of invitation to breast cancer screening. It was initiated in late 1977. The follow-up to the end of 1998 provides results at approximately the twentieth anniversary of the trial. A significant decrease in breast cancer death among women invited to screening was published 7-8 years after randomization and at 20-year follow up there is a significant 32% reduction in mortality associated with invitation to screening. The advent of screen-film mammographic screening with the ability to detect potentially fatal tumors at an early stage provides an opportunity to study the natural history of breast cancer at an earlier phase in its development than was possible in the past. Our findings show that breast cancer is not a systemic disease at its inception, but is a progressive disease and its development can be arrested by screening. Detection of <15 mm and lymph node negative invasive tumors will save lives and confer an opportunity for less radical treatment. …
Metadata
Title
The Swedish Two-County Trial 20-years on: updated mortality results and new insights from long-term follow-up
Authors
L Tabár
SW Duffy
B Viták
H-H Chen
UB Krusemo
Publication date
01-10-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr197

Other articles of this Special Issue 2/2000

Breast Cancer Research 2/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine